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Abstract
Chloroquine (CQ) is a cost effective antimalarial drug with a relatively good safety profile (or therapeutic index). However,
CQ is no longer used alone to treat patients with Plasmodium falciparum due to the emergence and spread of CQ-resistant
strains, also reported for P. vivax. Despite CQ resistance, novel drug candidates based on the structure of CQ continue to be
considered, as in the present work. One CQ analog was synthesized as monoquinoline (MAQ) and compared with a
previously synthesized bisquinoline (BAQ), both tested against P. falciparum in vitro and against P. berghei in mice, then
evaluated in vitro for their cytotoxicity and ability to inhibit hemozoin formation. Their interactions with residues present in
the NADH binding site of P falciparum lactate dehydrogenase were evaluated using docking analysis software. Both
compounds were active in the nanomolar range evaluated through the HRPII and hypoxanthine tests. MAQ and BAQ
derivatives were not toxic, and both compounds significantly inhibited hemozoin formation, in a dose-dependent manner.
MAQ had a higher selectivity index than BAQ and both compounds were weak PfLDH inhibitors, a result previously reported
also for CQ. Taken together, the two CQ analogues represent promising molecules which seem to act in a crucial point for
the parasite, inhibiting hemozoin formation.
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Introduction
Malaria is one of the most prevalent parasitic diseases in the
world. It affects approximately 500 million individuals throughout
the tropical and subtropical areas of developing countries and
causes considerable morbidity and mortality with about 800,000
deaths worldwide each year [1]. P. falciparum infection in non-
immune adults and children is often associated with severe
cerebral malaria. The global importance of this disease, current
limitations of vector control and the absence of an effective
vaccine, makes the development of therapeutic antimalarial drugs
the main strategy of malaria control [2].
CQ is a cost effective antimalarial drug with a relatively good
safety profile [3]. However, CQ is no longer used alone due to the
emergence and spread of P. falciparum CQ-resistant strains and,
more recently, of P. vivax [4–6]. Artemisinin-based combination
therapy (ACT) is the first line treatment in P. falciparum malaria
(WHO, 2009). However, the limited availability of ACT and the
decreased susceptibility of P. falciparum to artemisinin derivatives
[7–8] have required the development of novel antimalarial drugs
[9–11]. Previous studies have described the discovery of novel
antimalarial drugs through analysis of medicinal plants [12] and
through novel drug synthesis protocols [13–14], however, no new
active compound has been shown to be as effective as CQ.
Despite the resistance of P. falciparum to CQ, novel drug
candidates based on the structure of CQ continue to be considered
[15–18]. In the present work, CQ analogs were synthesized as
mono- and bisquinoline-based derivatives, referred as MAQ and
BAQ, respectively. The main structural aspects considered
included the maintenance of the 4-aminoquinoline pharmaco-
phore group and the presence of proton-accepting sites to increase
drug bioavailability in the digestive vacuole of the parasite. The
compounds were tested: (i) as blood schizonticides against P.
falciparum in vitro and against P. berghei malaria in mice; (ii) for their
in vitro cytotoxicity; (iii) for their ability to inhibit hemozoin
formation; and (iv) for their binding mode to lactate dehydroge-
nase and dimeric hematin in silico.
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Synthesis and characterization of CQ analogs
The structure of the two aminoquinoline derivatives, MAQ and
BAQ, and their synthesis strategy are depicted in Scheme S1. Both
CQ analogs possess the conserved 4-aminoquinoline moiety (a
crucial pharmacophore group), and have a chlorine substituent at
the 7 position on the quinoline ring, and, both have amino groups
on the alkyl chain [19]. MAQ, a new monoquinoline molecule,
and BAQ, a previously synthesized bisquinoline already tested
against P. falciparum and proven to be active [20], were prepared
from 4,7-dichloroquinoline and diethylenetriamine. These reac-
tions occurred via a SNAr synthesis step, which eliminated the use
of solvents [21]. MAQ and BAQ were obtained by controlling the
stoichiometric relationship between these reagents. The synthesis
protocol for the bisquinoline compound BAQ was described
previously [20].
BAQ and MAQ were isolated as white solids, which underwent
a satisfactory elemental analysis and were fully characterized by
NMR and IR spectroscopy. On the
1H NMR spectrum, MAQ
showed five of the expected signals of the aromatic region
(between 8.32 and 6.50 ppm) and four signals related to the
methylenic groups (between 3.47 and 2.78 ppm). The hydrogen
signals of the amino groups were either not present or had an
integration level lower than the predicted value due to the fast H/
D exchange with the deuterated solvent. In the
13C NMR
spectrum, it was possible to identify nine signals related to the
aromatic carbons (between 152 and 97 ppm) and the four signals
associated with the methylenic carbons (50 to 40 ppm). In the
infrared spectrum of MAQ, the typical absorption bands for this
kind of chemical structure were observed and the
1H NMR
spectrum was consistent with the five typical aromatic signals
(between 8.25 and 6.46 ppm). However, only two signals related to
the methylenic groups were observed due to the symmetry of the
molecule (3.45 and 2.95 ppm). In the
13C NMR spectrum of
BAQ, the expected nine signals related to the aromatic carbons
(between 152 and 97 ppm) and the two possible signals of the
methylenic carbons (46.8 and 41.8 ppm) were observed. The
infrared spectrum of BAQ exhibited the absorption bands
predicted for this structure.
BAQ and MAQ activities against P. falciparum in vitro
The 4-aminoquinoline derivatives MAQ and BAQ were
compared with CQ for their antiplasmodial activities against the
W2 clone of P. falciparum (CQ-resistant and mefloquine-sensitive)
and against a CQ-sensitive strain 3D7. All compounds showed
activity in the nanomolar range in the HRPII and hypoxanthine
tests (Table 1). The IC50 values were similar in both assays,
although somewhat lower for BAQ in the hypoxanthine test with
W2 parasites. As expected, the IC50 values of BAQ and MAQ
were lower with the CQ- sensitive 3D7 strain than with W2 CQ-
resistant in most tests.
Neither MAQ or BAQ were toxic against hepatoma (HepG2) or
kidney (BGM) cell lines, and important, the new CQ analog MAQ
was less toxic than BAQ, based on MTT assay (Table 2) or neutral
red method (data not shown). Additionally, the CQ analogs were
not lytic to human erythrocytes. Even at doses 100 times higher
than the IC50 values no hemolysis was detected.
The selectivity index- IS (the ratio between MDL50 and IC50)
was determined and both compounds had an IS greater than 90.
The IS was particularly high for MAQ, 384 and 1038, against
BGM and HepG2 cells respectively (Table 2). Nevertheless,
neither compound was better then CQ (IS.3083)
BAQ and MAQ were also active in vivo against rodent
malaria
The antimalarial activity of the new CQ analogs was evaluated
in mice with P. berghei and is summarized in Table 3. MAQ and
BAQ were active in vivo at a dose of 50 mg/kg on days 5, 8 and 10
days post-infection, at 25 mg/kg only MAQ was active. MAQ
caused a 95% reduction of parasitemia on day 5. However, only
CQ caused 100% suppression of parasitemia and increased the
animal survival, but the survival differences were not significant
from the other groups.
The antimalarial activity of BAQ and MAQ involves
inhibition of hemozoin formation
Whether anti P. falciparum activity of BAQ and MAQ involves
inhibition of hemozoin formation was evaluated using an indirect
in vitro test. Both compounds significantly inhibited hemozoin
formation in vitro (Figure 1) in a dose-dependent reaction. The
inhibition was more evident with MAQ than with BAQ or CQ
(Figure 1A).
Similarly, docking studies with MAQ and BAQ showed that the
MolDock Score energies between the antimalarials and the
dimeric hematin (Table 4) were approximately –100.000 kcal -
mol
–1. Both aminoquinoline derivatives, similar to CQ, were able
to interact with dimeric hematin to form a complex. The best
conformations (Figure 2) obtained for the complexes showed that
the aromatic rings of both compounds were parallel to the hematin
ferriprotoporphyrin group (Figure 3). Weak hydrogen bonds
(approximately 25.0 kcal mol
–1) corroborate previous studies
demonstrating that the hydrophobic interactions were the main
contributors for the binding between CQ and the dimer [22–23].
Table 1. The anti-P. falciparum activities of BAQ and MAQ
determined in parallel with chloroquine, by the ELISA anti-
HRPII assay or by
3H hypoxanthine incorporation.
Compounds W2 (CQ resistant) 3D7 (CQ sensitive)
IC50 (nM) HRPII Hypoxanthine HRPII Hypoxanthine
BAQ 55060.0 60620 3568 10567
MAQ 260620 320670 26626 6 65
CQ 12060.0 18060.0 6.960.9 7.461.2
All compounds were active at nanomolar doses in both tests.
IC50=dose that inhibits 50% of blood parasites growth, evaluated in three or
four different experiments for each test.
doi:10.1371/journal.pone.0037259.t001
Table 2. Cytotoxicity of BAQ and MAQ against a human
hepatoma cell line (HEPG2) and a monkey kidney cell line
(BGM) determined by the MTT assay.
Compounds MDL50 (mM) Selectivity index*
BGM HepG2 BGM HepG2
BAQ 50630 5060.0 90 90
MAQ 10060.0 270610 384 1038
CQ 37060.0 49060.0 3083 4083
Data expressed as the minimal lethal dose for 50% of cells (MDL50), used to
calculate the selectivity index against either cell.
*Selectivity index=MDL50//IC50.
doi:10.1371/journal.pone.0037259.t002
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to lactate dehydrogenase
Table 5 presents the H-bond energy and MolDock Scores of the
residues involved in H-bonds with NADH as well as the
protonated forms of chloroquine, BAQ and MAQ docked to
PfLDH. Figure 4 shows that these compounds presented the most
stable energy conformations in the binding site of NADH. This
suggests that they are NADH competitors. The H-bond energy
between the protonated chloroquine and the enzyme was
23.8 kcal mol
21, a high value compared with that of NADH
H-bond energy (235.3 kcal mol
21). The energy of interaction
between the enzyme and the protonated forms of MAQ were
approximately 2250.00 kcal mol
21. Furthermore, MAQ like the
protonated chloroquine, bound to the active site of PfLDH; BAQ-
1 and BAQ-2 presented the lowest energies, which were extremely
large when compared to NADH. These findings suggest that all
these compounds are weak inhibitors of PfLDH, as previously
reported for chloroquine [24].
Discussion
A large series of bisquinoline derivatives containing proton-
accepting amino groups on the aliphatic chain moiety has already
been described [19] and considered a promising class of
compounds for treating drug-resistant malaria parasites. Two
CQ analogs MAQ and BAQ were obtained as low-cost
antimalarial prototypes, which is important considering that
disease transmission is concentrated in developing countries and
is most frequent among the impoverished classes of several
endemic countries [9]. Comparisons between their antimalarial
activities aimed to evaluate the molecular structural-activity
relationship between mono- and bisquinoline compounds.
We showed that MAQ and BAQ are active in vitro against CQ-
resistant and CQ-sensitive P. falciparum parasites at nanomolar
doses in the hypoxanthine incorporation test and in an enzyme-
linked immunosorbent assay (ELISA), using antibodies against the
histidine-rich protein 2 (HRP-II), a parasite protein.Our results
show that MAQ, a new monoquinoline, has a higher IS, in
consonance with the tendency of a decreased toxicity when
comparing mono- to bisquinoline analogs. Such in vitro activity was
confirmed in vivo in mice infected with P. berghei; MAQ was more
effective as proven by parasitemia reduction in response to drug
treatment.
Further in vitro analysis showed that the compounds interacted
with dimeric hematin and inhibited heme polymerization.
Although the mechanism of action of CQ is not well understood,
several experimental studies describe the interaction between CQ
and the dimeric form of heme [25,26,27,28]. This interaction
seems responsible for the inhibition of hemozoin formation, a
hypothesis further supported by docking studies, which also
suggest that all protonated forms of MAQ and BAQ interact with
the rings parallel to the heme group, as described previously for
CQ [26,27,28,29].
The presence of two quinoline moieties in BAQ increases the
probability of hydrophobic interactions when compared with
MAQ and also results in lower docking energies for all protonation
states of the amino groups. The results of this study suggest that
Table 3. Antimalarial activity of BAQ and MAQ in mice infected with P. berghei after treatment with daily doses of the compounds
during three consecutive days.
Compounds Dose (mg/kg) Percent reduction of parasitemia* Time of survival (in days)
56 86 106
BAQ 25 64 26 37 2562
50 81 75 43 2461
MAQ 25 91 61 70 2461
50 95 71 76 2561
CQ 20 100 100 100 .30
Control 0 0 0 0 1967
*Reductions #30% were considered as inactive, 30–50% as partially active and $50% as active drugs.
Figure 1. Inhibition of hemozoin formation by the CQ analogs BAQ and MAQ (mean ± SD from triplicates), in two different
experiments. Statistical differences as compared to drug-free controls are indicated in each graph by an asterisk (p,0.05). The p and r values
represent the statistical correlation analyses.
doi:10.1371/journal.pone.0037259.g001
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more effective at inhibiting heme polymerization.
Experimental and modeling studies have shown that chloro-
quine binds to PfLDH, suggesting that CQ possesses another
mechanism of drug action or a mechanism complementary to the
one already proposed [24,29]. Although PfLDH is not a direct
chloroquine target, experimental data have shown its weak
binding to chloroquine [30]. The existence of this shared target-
binding site suggests that PfLDH is related to drug effectiveness.
The docking data (Figure 4) suggest that the protonated forms of
BAQ and MAQ present the most stable energetic conformations
at the binding site of NADH inside PfLDH. The H-bond energy
and MolDock Scores, the residues involved in the H-bonds with
NADH and the protonated forms of chloroquine as well as BAQ
and MAQ binding to PfLDH (Table 5) suggest that these
compounds are NADH competitors. The H-bond energy between
protonated chloroquine and the enzyme is 23.8 kcal mol
21,a
high value compared with the H-bond energy of NADH
(235.3 kcal mol
21). The energies of interaction between the
enzyme and the protonated forms of MAQ were approximately –
250.0 kcal mol
21. Furthermore, MAQ compounds showed a
similar behavior at the active site of PfLDH compared with
protonated chloroquine. BAQ-1 and BAQ-2 possessed the lowest
energies, which were extremely large compared with NADH.
Overall, these findings suggest that all of these compounds are
weak inhibitors of PfLDH, as previously reported for chloroquine
[22–23].
One of the recent strategies to develop effective antimalarial
agents is based on the development of metal-drugs [31,32,33].
Thus, MAQ and BAQ were associated with metals readily
available to be tested for their antimalarial activity, in promising
ongoing tests (data not shown). Metallocomplexed drugs, consid-
ered first-line anticancer drugs [34,35], are increasingly used to
develop anti-parasitic agents [36,37,38].
Materials and Methods
Reagents and drug synthesis
All reactions for drug synthesis were performed under a 100%
argon atmosphere using a dual vacuum/argon line and standard
Schlenk techniques. Reagents and solvents were purchased from
Sigma Aldrich and used without further purification. The IR
spectra were recorded on a Varian 640-IR with an ATR device
and the elementary analyses were conducted at the analytical
center, University of Sa ˜o Paulo. The
1H NMR spectra were
recorded at 400.130 MHz and the
13C NMR spectra at
100.613 MHz on a Bruker instrument (Bruker Avance 400) and
were externally referenced to the tetramethylsilane (TMS).
Chemical shifts (d) and coupling constants (J) were expressed in
ppm and Hz, respectively. The melting or decomposition points of
the structures were determined on a MQAPF 302 apparatus.
Synthesis of the 4-aminoquinolines, MAQ and BAQ
MAQ, N
1-(2-aminoethyl)-N
2-(7-chloroquinol-4-yl)ethane-1,2-diamine,
was prepared according to the synthesis procedures described by
Musonda and collaborators [39]. Briefly, a mixture of 4,7-
dichloroquinoline (0.98 g, 4.9 mmol) and diethylenetriamine
(2.7 mL, 25 mmol) was heated at 80uC for 1 h without stirring,
following by heating at 135uC for 3 h with stirring. The mixture
was cooled to room temperature, alkalized with an aqueous
solution of 10% NaOH (30 mL), extracted with hot EtOAc
(3650 mL) and dried over Na2SO4. The solvent was removed
under vacuum and the residue was crystallized with CH2Cl2/
hexane, thereby leading to a white solid. Chemical and spectral
analyses revealed the following: Yield: 0.52 g, 40%. M.F:
C13H17ClN4; M.M.: 264.75 g/mol. Elem. Anal., theoretical:
C13H17ClN4, C, 58.98; H, 6.47; N, 21.16, experimental:
C13H17ClN4.H2O, C, 55.23; H, 6.54; N, 19.22. M.P.: 99–
100uC; I.R. (nma ´x cm
21): 3256 (Ar- NH); 3065 (CH quinoline
Figure 2. Chemical structures of the protonated forms of the CQ analogs BAQ and MAQ.
doi:10.1371/journal.pone.0037259.g002
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(C=C quinoline ring); 1449 (CH2); 1280 (Ar-C-N); 1133 (C-N);
874, 795 and 761 (d=C-H out-of-plane aromatic ring). RMN
1H
(400 MHz, CD3OD): d 1.93 (s, NH amine), 2.78 (t, J=5.76 Hz,
2H, CH2-16), 2.85 (t, J=5.76 Hz, 2H, CH2-15), 2.95 (t,
J=6.38 Hz, 2H, CH2-13), 3.47 (t, J=6.38 Hz, 2H, CH2-12),
3.70 (ls, NH aniline), 6.50 (d, J=5.71 Hz, 1H, Ar-H C-3), 7.35
(dd, J=9.01 Hz, J=2.14 Hz, 1H, Ar-H C-6), 7.73 (d,
J=2.14 Hz, 1H, Ar-H C-8), 8.07 (d, J=9.01 Hz, 1H, Ar-H
C-5), 8.32 (d, J=5.62 Hz, 1H, Ar-H C-2). RMN
13C (100 MHz,
CD3OD): d 151.1 (C-2), 98.28 (C-3), 151.4 (C-4), 124.6 (C-5),
123.08 (C-6), 134.9 (C-7), 126.2 (C-8), 148.2 (C-9), 117.32 (C-10),
50.03 (C-12), 42.08 (C-13), 39.9 (C-15), 38.46 (C-16).
BAQ, N
1-(7-chloroquinol-4-yl)-N
2-{2-[(7-chloroquinol-4-il)ami-
no]ethyl}ethane-1,2-diamine, was synthesized according to the syn-
thesis procedures described by Zhang and collaborators [40].
Briefly, a mixture of 4,7-dichloroquinoline (1.20 g, 6.00 mmol)
and diethylenetriamine (0.22 mL, 2.00 mmol) was heated at 80uC
for 6 h without stirring and then at 130uC for 3 h with stirring.
The reaction mixture was cooled to room temperature and the
resulting solid that formed was washed with an aqueous solution of
10% NaOH (30 mL) and recrystallized with MeOH/water. The
solid was recuperated by filtration and dried under vacuum, which
lead to a white solid. Chemical and spectral analyses revealed the
following: Yield: 0.43 g, 50%. M.F: C22H21Cl2N5; M.M.:
426.34 g/mol. Elem. Anal., theoretical: C22H21Cl2N5, C, 61.98;
H, 4.96; N, 16.43; experimental: C22H21Cl2N5.4H2O, C, 53.03;
H, 4.91; N, 14.07. M.P.: 212–215uC; IR. (nmax in cm
21): 3272
(Ar- NH); 3071 (CH quinoline ring); 2901 and 2843 (CH2a s / s );
1608, 1576 and 1531 (C=C quinoline ring); 1441 (CH2); 1328
(Ar-CN); 1136 (C-N); 865 and 798 (d out-of-plane aromatic ring).
1H RMN (400 MHz, CD3OD): d 2.97 (t, J=6.22 Hz, 2H, CH2-
13), 3.45 (t, J=6.24 Hz, 2H, CH2-12), 6.45 (d, J=5.69 Hz, 1H,
Ar-H C-3), 7.20 (dd, J=9.01 Hz, J=2.14 Hz, 1H, Ar-H C-6),
Figure 3. Compounds docked in dimeric hematin. (A) Protonated CQ, (B) MAQ-1, (C) MAQ-2, (D) MAQ-3, (E) BAQ-1, (F) BAQ-2.
doi:10.1371/journal.pone.0037259.g003
Table 4. Docking energies of the protonated forms of the CQ
analogs BAQ and MAQ.
Structure
H Bond Energy
(kcal mol
21)
MolDock Score
(kcal mol
21)
Protonated CQ 23.43 2105.97
MAQ-1 21.95 2100.57
MAQ-2 25.00 292.16
MAQ-3 23.50 276.50
BAQ-1 22.50 2119.69
BAQ-2 22.50 2116.89
doi:10.1371/journal.pone.0037259.t004
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5), 8.24 (d, J=5.61 Hz, 1H, Ar-H C-2). RMN
13C (100 MHz,
MeOD): d 150.9 (C-2), 98.3 (C-3), 151.2 (C-4), 124.6 (C-5), 122.6
(C-6), 134.9 (C-7), 126.2 (C-8), 148.14 (C-9), 117.3 (C-10), 46.8 (C-
12), 41.8 (C-13).
Continuous cultures of P. falciparum
P. falciparum blood parasites (W2 clone, CQ-resistant and
mefloquine-sensitive) were maintained in continuous culture as
previously described [41] with slight modifications [42]. The 3D7
strain, CQ- sensitive, originally received from the New York
University Medical School, was also used. Briefly, the parasites
Figure 4. Best conformations of the protonated forms of chloroquine, MAQ and BAQ (in green) in the binding pocket of NADH (in
CPK) as generated by the MVDH software. (A) Protonated chloroquine, (B) MAQ-1, (C) MAQ-2, (D) MAQ-3, (E) BAQ-1, (F) BAQ-2.
doi:10.1371/journal.pone.0037259.g004
Table 5. Docking results of NADH and the protonated forms of chloroquine, BAQ and MAQ in the active site of PfLDH.
Ligands H Bond Energy (Kcal mol
21) MolDock Score (Kcal mol
21) Residues (H Bond interactions)
NADH 235.3 2432.3 Asp53, Thr97, Gly29, Tyr85, Leu25, Met30,
His126, Val55, Glu122, Phe100, His195
Protonated
Chloroquine
23.8 2252.4 Gly99
MAQ-1 28 2247.5 Asp53, Gly99
MAQ-2 22.9 2266.2 Asp53, Gly99
MAQ-3 20.5 2249 Asp53
BAQ-1 217.4 2337.2 Gly99, Thr97, Asp53, Asn140
BAQ-2 0 2297.3 -
doi:10.1371/journal.pone.0037259.t005
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+) with complete
medium (RPMI 1640 supplemented with 10% human serum
blood group A
+, 2% glutamine and 7.5% NaHCO3) in Petri dishes
in a candle jar or in a 25-cm culture flask in a defined atmosphere
(with 3% O2,5 %C O 2 and 91% N2). Human erythrocytes (A
+)
and serum blood group A+ were kindly donated by Center of
Hemotherapy and Hemathology of Minas Gerais (HEMOMI-
NAS). Immediately before the tests, ring stage-parasites were
synchronized in sorbitol [43]. Synchronized parasites were stained
with orange green in pre-dried coverslips [44] then immediately
examined under a fluorescent microscope. The suspension was
adjusted for parasitemia and hematocrit as described below for
each test. The infected red blood cells were distributed in a 96-well
microtiter plate (Corning, Santa Clara, CA, EUA) at 180 mL/well,
in which 20 mL of the test drugs and controls were previously
diluted at different concentrations (400-0.625 ng/mL) in 0.005%
DMSO (v/v) (Sigma, USA).
In vitro assays with P. falciparum infected erythrocytes
The effects of BAQ and MAQ on the W2 and 3D7 P. falciparum
blood cultures were assayed through the incorporation of
3H
hypoxanthine (PerkinElmer, Waltham, MA, EUA) [45] and with
monoclonal antibodies to the parasite histidine and alanine-rich
protein (HRPII) (MPFM ICLLAB-55AH, MPFG55P ICLLABH,
USA) (Noedl 2002). The [
3H]-hypoxanthine assay was performed
at 1% parasitemia and 1% hematocrit and the level of isotope
incorporation was read in a beta-counter (PerkinElmer, Waltham,
MA, EUA). The anti-HRPII test was performed at 0.05%
parasitemia and 1.5% hematocrit and the HRPII quantification
was read at 450 nm in a spectrophotometer (Spectra-
Max340PC
384, Molecular Devices). The results of three of these
drug activity assays were expressed as the mean of the half-
maximal inhibitory dose (IC50) and compared with the drug-free
controls. Curve-fitting was performed using Origin 8.0 software
(OriginLab Corporation, Northampton, MA, USA) [46].
Inhibition of hemozoin assay
The hemozoin inhibition assay was performed as described by
Ncokazi et al., (2002) [47] with some modifications. Briefly,
10.1 mL of the aminoquinoline derivatives at different concentra-
tions (40-0.62 mg/mL) and 101.2 mL of the hematin stock solution
(1.68 mM in 0.1 M NaOH) were combined in triplicate in a flat-
bottomed 96-well plate. The solutions were further mixed and
58.7 mL of acetate solution (12.9 M, pH 5.0) then added to each
well. After incubation at 60uC, 80 mL of 30% (v/v) pyridine
solution in 20 mM HEPES, pH 7.5, were added at room
temperature. The solids formed were resuspended and allowed
to settle for 15 min at room temperature. Then, 38 mL of the
supernatant were transferred to a new plate and diluted to 250 mL
with a 30% (v/v) pyridine solution (20 mM HEPES, pH 7.5). The
color reaction was read in a spectophometer at 405 nm and the
results were expressed as the concentration of free heme in each
well, which was calculated from the standard absorbance curve of
a known hemin solution. CQ was used as a positive control and
the cut off was determined by the amount of free heme in the drug-
free control. Each compound was evaluated in two different
experiments.
Antimalarial tests against P. berghei in mice
A suppressive parasite growth test was used with P. berghei,
NK65 strain (originally received from the New York University
Medical School) infected mice as described previously [48] with
some modifications [49]. Briefly, adult Swiss outbred mice
(2062 g weigh) were inoculated with 1610
5 red blood cells
infected with P. berghei, by intraperitoneal route. The infected mice
were maintained together for at least 2 h and then divided
randomly into groups of 3–5 animals per cage, which were
subsequently treated with 25 and 50 mg/kg of each compound
diluted in DMSO 3% (v/v) given daily by oral gavage for three
consecutive days. Two control groups were used in parallel, one
treated with CQ (20 mg/kg) and one with the vehicle. Blood
smears from mouse tails were prepared on days 5, 8 and 10 post-
infection and then methanol-fixed, stained with Giemsa and
examined microscopically. The parasitemia was evaluated and the
percent inhibition of parasite growth calculated in relation to the
untreated control group (considered 100% growth) using the
following equation: [(C - T)/C] 6100; where C is the parasitemia
in the control group and T is the parasitemia in the treated group.
The use of laboratory animals was approved by the Ethics
Committee for Animal Use of the Oswaldo Cruz Foundation -
Fiocruz (CEUA L-0046/08).
Cell cultures and cytotoxicity tests
The human hepatoma cell line (HepG2) was originally received
from the New University of Lisbon, and the monkey kidney cell
line (BGM) from the Federal University of Minas Gerais. These
cells were cultured in 75 cm
2 plates with RPMI 1640 medium
supplemented with 10% heat-inactivated fetal calf serum and
40 mg/L gentamicine in a 5% CO2 atmosphere at 37uC. For the
in vitro tests, a confluent cell monolayer was trypsinized, washed
with culture medium, distributed in a flat-bottomed 96-well plate
(5610
3 cells/well) and incubated for 18 h at 37uC to ensure cell
adherence.
The cytotoxicity was evaluated with the MTT assay, 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide [50].
Briefly, the HepG2 and BGM cell lines were incubated with
20 mL of the compounds at different concentrations (1000-1 mg/
mL) for 24 h in a 5% CO2 and air atmosphere at 37uC. For the
MTT assay, which evaluates mitochondrial viability, 20 mLo f
MTT solution (5 mg/mL) were added and the plates were
incubated for a further 3 h. After incubation, the supernatant was
carefully removed from the wells, followed by the addition of
100 mL DMSO with thorough mixing. The optical density at 570
and 630 nm (background) was determined on an ELISA reader
(SpectraMax340PC
384, Molecular Devices).
The neutral red assay was used to evaluate cell viability by the
accumulation of dye in the viable cell lysosome [51]. Briefly, the
cells were incubated for 2 h with 100 mL of a neutral red solution
(100 mg/mL). Then, the supernatants were discard and 200 mLo f
a formaldehyde (0.5% v/v) and CaCl2 (1%) solution were added,
which was followed by another 5 min incubation. Finally, the
supernatant was removed, then 100 mL of an alcohol-acid solution
added to the sediment. The absorbance was read at 540 nm on an
ELISA reader (SpectraMax340PC
384, Molecular Devices). Cell
viability was expressed as the percentage of control absorbance
obtained in untreated cells after subtracting the absorbance of the
appropriate background. Lastly, the minimum lethal dose for 50%
of the cells (MLD50) was determined as previously described [52].
Hemolysis assay
The test and control compounds were diluted in a 0.2% (v/v)
DMSO solution and incubated (0–50 mg/mL) with a human
erythrocytes suspension (1% hematocrit) at 37uC for 30 min in a
shaking water bath. The mixtures were centrifuged at 1000 g for
10 min and the absorbance of the supernatants was measured at
540 nm in an ELISA reader (SpectraMax340PC
384, Molecular
Devices). The hemolytic rate was calculated in relation to the
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to be 100% [53].
Docking energy calculations
The 3D optimized structure of dimeric hematin was taken from
our previous studies [29]. The structures of CQ and its analogs
were built using the Gaussian View software and optimized using
Gaussian 03 [54]. The structural analysis of CQ analogs (BAQ
and MAQ) was performed and all possible protonation forms in
the biological medium were considered (Figure 2). The geometry
optimizations and partial atomic charge distributions were
performed using the B3LYP/3-21G level of theory. The calcula-
tions for the docking energies were performed with Molegro
Virtual Docker (MVD) software [55] as described previously [25].
The algorithm used in the docking studies was the MolDock
Score, which is an adaptation of the Differential Evolution (DE)
algorithm [53]. The MolDock Score was used because it yields a
higher docking accuracy than other state-of-the-art docking
algorithms (MVD: 87%, Glide: 82%, Surflex: 75%, FlexX: 58%)
[46].
The 3D structure of PfLDH complexed with NADH and the
substrate oxamate used in the present work was obtained from the
Protein Data Bank (PDB) file 1LDG [56,57]. We performed
flexible docking studies (considering the presence of water
molecules in the crystal) with the protonated forms of BAQ and
MAQ to compare these interactions with protonated chloroquine
at the active site of PfLDH.
Supporting Information
Scheme S1 Synthesis of MAQ and BAQ.
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